SEER Seer

Seer to Participate in Upcoming September Investor Conferences

Seer to Participate in Upcoming September Investor Conferences

REDWOOD CITY, Calif., Sept. 08, 2023 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced company management will be participating in the following investor conferences:

  • Morgan Stanley 21st Annual Global Healthcare Conference in New York, NY.

    Fireside chat on Wednesday, September 13th at 12:15 p.m. Eastern Time

  • Gilmartin Group Emerging Growth Company Showcase, Virtual.

    Presentation on Thursday, September 21st at 1:30 p.m. Eastern Time

A live webcast of the sessions will be available on the Investor section of Seer’s website at investor.seer.bio. Archived replays will be available on the company’s website following the conference.

About Seer

Seer™ is a life sciences company developing transformative products that open a new gateway to the proteome. Seer’s Proteograph™ Product Suite is an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation and software to perform deep, unbiased proteomic analysis at scale in a matter of hours. Seer designed the Proteograph workflow to be efficient and easy to use, leveraging widely adopted laboratory instrumentation to provide a decentralized solution that can be incorporated by nearly any lab. Seer’s Proteograph Product Suite is for research use only and is not intended for diagnostic procedures. For more information, please visit .

Investor Contact:

Carrie Mendivil

Media Contact:

Karen Possemato



EN
08/09/2023

Underlying

SEERSeer

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Seer

 PRESS RELEASE
Free
SEER SEER

Seer Reports Second Quarter 2025 Financial Results and Reiterates Full...

Seer Reports Second Quarter 2025 Financial Results and Reiterates Full Year 2025 Outlook Revenue grew 32% year-over-year, driven by increased product sales and service revenue Launched new high-throughput Proteograph® ONE assay and SP200 automation instrument REDWOOD CITY, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today reported financial results for the second quarter ended June 30, 2025. Recent Highlights Achieved revenue of $4.1 million for the second quarter of 2025...

August 6, 2025 1 EN
 PRESS RELEASE
Free
SEER SEER

Seer to Participate in the Canaccord Genuity 45th Annual Growth Confer...

Seer to Participate in the Canaccord Genuity 45th Annual Growth Conference REDWOOD CITY, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that the company will be participating in the upcoming Canaccord Genuity 45th Annual Growth Conference in Boston, MA. Seer’s management is scheduled to participate in a fireside chat on Wednesday, August 13th at 9:00 a.m. Eastern Time / 6:00 a.m. Pacific Time. A live webcast of the session will be available on the Investor section of Seer’s websit...

July 31, 2025 1 EN
 PRESS RELEASE
Free
SEER SEER

Seer to Report Second Quarter 2025 Financial Results on August 6, 2025

Seer to Report Second Quarter 2025 Financial Results on August 6, 2025 REDWOOD CITY, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that it will report financial results for the second quarter 2025 on Wednesday, August 6, 2025. Company management will be webcasting a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the Investor section of Seer’s website at investor.seer.bio. An archived replay will be avai...

July 22, 2025 1 EN
 PRESS RELEASE
Free
SEER SEER

Seer’s Proteograph Platform Enables Unprecedented 20,000-Sample Proteo...

Seer’s Proteograph Platform Enables Unprecedented 20,000-Sample Proteomics Study with Korea University to Develop AI-Driven Diagnostics for Cancers in Young Adults First-of-its-kind study will use Seer’s next-generation workflow to identify early-onset cancer biomarkers and power deep, unbiased mass spectrometry-based proteomics Seer’s new Proteograph ONE Assay to accelerate analysis and reduce costs, making large-scale studies feasible  REDWOOD CITY, Calif., June 01, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insight...

June 1, 2025 1 EN
 PRESS RELEASE
Free
SEER SEER

Seer Redefining Deep Unbiased Proteomics with Launch of New Proteograp...

Seer Redefining Deep Unbiased Proteomics with Launch of New Proteograph Workflow at ASMS 2025, Enabling Previously Unattainable Scale and Efficiency REDWOOD CITY, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced the launch of its new Proteograph® Product Suite, featuring the Proteograph ONE Assay and SP200 Automation Instrument—its most advanced solution yet for scalable, high-resolution, mass spec-based proteomics. Seer’s newest innovation, debuting at the upcoming American Society for Mass Sp...

May 29, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch